BioMarin Pharmaceuticals
BMRN
294 hedge funds and large institutions have $10.1B invested in BioMarin Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 112 increasing their positions, 113 reducing their positions, and 24 closing their positions.
80% more call options, than puts
Call options by funds: $74.9M | Put options by funds: $41.5M
67% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 24
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
27% more capital invested
Capital invested by funds: $7.98B → $10.1B (+$2.13B)
5% more funds holding
Funds holding: 280 → 294 (+14)
1% less repeat investments, than reductions
Existing positions increased: 112 | Existing positions reduced: 113
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$109M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$63.1M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$35.1M |
| 4 |
ACPU
Arrowgrass Capital Partners (US)
Dover,
Delaware
|
+$31.6M |
| 5 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
+$31.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$137M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$83.2M |
| 3 |
Sands Capital Management
Arlington,
Virginia
|
-$71.5M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$57.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$46.3M |
BMRN Hedge Fund Activity: Q3 2013 in Review
294 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q3 2013, worth a combined $10.1B — up 27% from $7.98B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new BMRN positions and 24 closed out — a net gain of 16 holders — while 112 added to existing stakes and 113 trimmed.
The largest buyer was Jennison Associates, adding an estimated $109M. The largest seller was Capital World Investors, cutting an estimated $137M.
- 294 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q3 2013, up from 280 in Q2 2013.
- Funds reported $10.1B of BioMarin Pharmaceuticals stock for Q3 2013, up 27% quarter-over-quarter.
- 40 funds opened new BioMarin Pharmaceuticals positions in Q3 2013 and 24 closed out, a net change of +16 holders.
- The largest BioMarin Pharmaceuticals buyer in Q3 2013 was Jennison Associates, an estimated $109M added.
- The largest BioMarin Pharmaceuticals seller in Q3 2013 was Capital World Investors, an estimated $137M sold.
Based on aggregated 13F filings for Q3 2013.